A. Young

发表

From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.

G. Pairaudeau, A. Bailey, E. Cadogan, 2012, Bioorganic & medicinal chemistry letters.

Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists.

G. Pairaudeau, A. Bailey, E. Cadogan, 2011, Bioorganic & medicinal chemistry letters.

Design-driven LO: the discovery of new ultra long acting dibasic β2-adrenoceptor agonists.

G. Pairaudeau, A. Bailey, E. Cadogan, 2011, Bioorganic & medicinal chemistry letters.

QSAR and the rational design of long-acting dual D2-receptor/beta 2-adrenoceptor agonists.

R. Austin, P. Barton, A. Davis, 2003, Journal of medicinal chemistry.

Dual D2 Dopamine Receptor and β2-Adrenoceptor Agonists for the Modulation of Sensory Nerves in COPD

P. Newbold, A. Young, I. Dougall, 2001 .

AZD3199: A potent and selective β2-adrenergic receptor agonist with rapid onset of action

R. Austin, G. Pairaudeau, D. Nicholls, 2011, ATS 2011.

The In Vivo Profile Of AZD3199: A Novel, Fast Acting B2-Agonist With A Long Duration Of Action

G. Pairaudeau, D. Nicholls, S. Connolly, 2011, ATS 2011.

Duration of action of inhaled vs. Intravenous beta(2)-adrenoceptor agonists in an anaesthetized guinea-pig model.

A. Young, I. Dougall, S. Mohammed, 2000, Pulmonary pharmacology & therapeutics.

Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.

G. Pairaudeau, A. Bailey, E. Cadogan, 2014, ACS medicinal chemistry letters.

The discovery of AZD 3199 A new inhaled ultra-long acting 2 receptor agonist with rapid onset of action

David, A. Bailey, E. Cadogan, 2014 .

Micronucleus induction in the bone marrow of rats by pharmacological mechanisms. II: long-acting beta-2 agonism.

D. Nicholls, M. O’Donovan, C. Fred, 2013, Mutagenesis.

Characteristics of AZD9708, a novel, selective β2-adrenoceptor agonist with rapid onset and long duration of action.

R. Austin, E. Cadogan, D. Nicholls, 2012, Pulmonary pharmacology & therapeutics.

Dual D2-receptor and beta2-adrenoceptor agonists for the treatment of airway diseases. 1. Discovery and biological evaluation of some 7-(2-aminoethyl)-4-hydroxybenzothiazol-2(3H)-one analogues.

R C Brown, A M Davis, W. T. Simpson, 1998, Journal of medicinal chemistry.

Dual dopamine D2 receptor and beta2-adrenoceptor agonists for the treatment of chronic obstructive pulmonary disease: the pre-clinical rationale.

D. Jackson, A. Young, I. Dougall, 2003, Respiratory medicine.